News 2023-03-25
Porton Released 2022 CSR Report
Porton Pharma Solutions Ltd. recently released 2022 CSR Report which is its seventh CSR report since IPO. This report demonstrates the company's ideas and achievements in fulfilling social responsibility from aspects such as "improving corporate governance", "providing high-quality services", "empowering employee development", "practicing green development", and "participating in community co-development".
Portonisalways committed to sustainable development，adopting a development model that balances economic benefits with gover-nance, environment,and social welfare, in order tocontinuously enhance the company'sriskresistanceandsustainable business capabilities.
Currency:RMB
Others
More
News 2025-07-31
Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization
Overcoming the challenge of efficient synthesis of PKMYT1 inhibitor Lunresertib
News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
